Isabel Syndikus
Impact in
- Pulmonary and Respiratory Medicine top 0.2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Radiation top 0.5%
- Advanced Radiotherapy Techniques
Papers in
-
- Prostate Cancer Diagnosis and Treatment 40
- Prostate Cancer Treatment and Research 19
-
- Breast Cancer Treatment Studies 12
- Co-authors
- David Paul Dearnaley (20 shared papers)John D. Graham (10 shared papers)Matthew Robert Sydes (7 shared papers)Christopher D. Scrase (13 shared papers)Robert Anthony Huddart (6 shared papers)Chakiath C. Jose (4 shared papers)John H. L. Matthews (3 shared papers)Edwin G.A. Aird (3 shared papers)
- Journals
- International Journal of Radiation Oncology*Biology*Physics (17 papers)The Lancet Oncology (14 papers)Clinical Oncology (12 papers)Radiotherapy and Oncology (11 papers)European Urology (6 papers)
- Partner nations
- United KingdomCanadaUnited States
In The Last Decade
Isabel Syndikus
98 papers receiving 10.7k citations
Isabel Syndikus's Hit Papers
Peers
Comparison fields: 5 of 119
- Pulmonary and Respiratory Medicine 6.0k
- Radiation 1.4k
- Cancer Research 1.8k
- Radiology, Nuclear Medicine and Imaging 2.2k
- Oncology 2.2k
Countries citing papers authored by Isabel Syndikus
This map shows the geographic impact of Isabel Syndikus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Syndikus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Syndikus more than expected).
Fields of papers citing papers by Isabel Syndikus
This network shows the impact of papers produced by Isabel Syndikus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Syndikus. The network helps show where Isabel Syndikus may publish in the future.
Co-authors
The 25 scholars most cited alongside Isabel Syndikus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 104 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer Hit paper breakdown → | 2013 | 2650 |
| 2 | Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial Hit paper breakdown → | 2016 | 1008 |
| 3 | Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial Hit paper breakdown → | 2020 | 776 |
| 4 | Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial Hit paper breakdown → | 2007 | 747 |
| 5 | Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial Hit paper breakdown → | 2019 | 533 |
| 6 | 2017 | 453 | |
| 7 | Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial Hit paper breakdown → | 2014 | 399 |
| 8 | Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial Hit paper breakdown → | 2014 | 384 |
| 9 | 2011 | 260 | |
| 10 | Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Hit paper breakdown → | 2022 | 239 |
| 11 | 2011 | 214 | |
| 12 | 2020 | 208 | |
| 13 | 2014 | 182 | |
| 14 | 2015 | 145 | |
| 15 | 2020 | 144 | |
| 16 | 2017 | 140 | |
| 17 | 2022 | 135 | |
| 18 | 2012 | 133 | |
| 19 | 2015 | 115 | |
| 20 | 2013 | 109 |
About Isabel Syndikus
Isabel Syndikus is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Radiation, Radiology, Nuclear Medicine and Imaging and Pathology and Forensic Medicine, having authored 104 papers that have together received 10.9k indexed citations. Recurring topics across this work include Prostate Cancer Diagnosis and Treatment (40 papers), Prostate Cancer Treatment and Research (19 papers), Breast Cancer Treatment Studies (12 papers), Advanced Radiotherapy Techniques (11 papers), Lymphoma Diagnosis and Treatment (9 papers), Bladder and Urothelial Cancer Treatments (7 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Glioma Diagnosis and Treatment (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (6.0k citations), Radiation (1.4k citations), Cancer Research (1.8k citations), Radiology, Nuclear Medicine and Imaging (2.2k citations) and Oncology (2.2k citations). Isabel Syndikus has collaborated with scholars based in United Kingdom, Canada and United States. Frequent co-authors include David Paul Dearnaley, John D. Graham, Matthew Robert Sydes, Christopher D. Scrase, Robert Anthony Huddart, Chakiath C. Jose, John H. L. Matthews, Edwin G.A. Aird, John Martin Russell and Jeremy Laurence Millar. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, The Lancet Oncology, Clinical Oncology, Radiotherapy and Oncology and European Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.